Trial Profile

Real-world Patient Profile and Treatment Persistence of Ocrelizumab in Multiple Sclerosis: A Retrospective Analysis in Latin America

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 04 Aug 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ocrelizumab (Primary)
Indications Multiple sclerosis
Focus Adverse reactions; Pharmacodynamics
Acronyms RWD_ocre

Most Recent Events

07 Aug 2019 Planned primary completion date changed from 1 Jul 2019 to 1 Aug 2019.
07 Aug 2019 Status changed from not yet recruiting to recruiting.
31 Dec 2018 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com